Monthly Archives

May 2019

skin microdyalisis

Skin microdialysis: methods, applications and future opportunities – an EAACI position paper

By | Selected articles

Katrine Y. Baumann, Martin K. Church, Geraldine F. Clough, Sven Roy Quist, Martin Schmelz, Per Stahl Skov, Chris D. Anderson, Line Kring Tannert, Ana Maria Giménez‑Arnau, Stefan Frischbutter, Jörg Scheffel and Marcus Maurer

(2019) Clinical and Translational Allergy

An EAACI Task Force on Skin Microdialysis was formed to gain knowledge about the technique and its applications in chronic inflammatory skin diseases, such as atopic dermatitis, chronic urticaria, psoriasis and other hypersensitivity reactions.

Skin microdialysis is a versatile sampling technique that can be used to recover soluble endogenous and exogenous molecules from the extracellular compartment of human skin. It is minimally invasive and can be applied in both clinical and preclinical settings, however it has still not reached its full potential use as a tool to explore pathophysiological mechanisms of allergic and inflammatory reactions in the skin.

Thin tubular dialysis membranes are inserted into the dermis or the subcutis and perfused at a low speed with a physiological solution. Molecules soluble in the extracellular fluid diffuse into the tubular microdialysis membrane and are collected in small vials for analysis.

Signs and symptoms of urticaria (itchy wheals and angioedema) can be induced by skin provocation with relevant triggers, which makes skin microdialysis ideal for the investigation of inducible urticaria. It has also been used to monitor the therapeutic effect of desensitization or antihistamines in cold urticaria patients by measuring histamine or cytokine release in response to cold provocation. It has shown that cold challenged patients with cold urticaria treated with increased doses of bilastine, significantly reduced late phase histamine and proinflammatory cytokine release.

In conclusion, there is still a huge potential for skin microdialysis to become a standard and routinely used technique in experimental dermatology and allergology, as it provides quantifiable data of the mediators involved in the inflammatory response in situ.

This document is only available for registered healthcare professionals

Login
rinitis-alergica-asma

Role of innate lymphoid cells in allergic diseases

By | Selected articles

M. Asghar Pasha, Gargi Patel, Russell Hopp and Qi Yang

(2019) Allergy and Asthma Proceedings

La identificación de ILC2 en pacientes con rinitis alérgica, asma y dermatitis atópica indica que estas células pueden representar un nuevo objetivo terapéutico. En esta revisión se discute la comprensión actual de la biología de ILC2 y su función y regulación en diversas enfermedades alérgicas.

This document is only available for registered healthcare professionals

Login
Bilastina y anticuerpos anti-

The real-life effectiveness and safety of omalizumab updosing in patients with chronic spontaneous urticaria

By | Articles about Bilastine

Andac Salman and Elif Comert

(2019) Journal of Cutaneous Medicine and Surgery

A retrospective cohort study was conducted to investigate the effectiveness and safety of 450 mg of omalizumab in chronic spontaneous urticaria.

Omalizumab is a third-line treatment for chronic spontaneous urticaria, however there are not enough studies regarding its use in patients that are unresponsive to regular doses of omalizumab.

A total of 72 patients were included, according to their Urticaria Activity Score over 7 days and the Urticaria Control Test and divided in two groups. Group 1 (n=59) included those showing a complete response to omalizumab 300 mg and group 2 (n=13) included those who received at least 3 doses of omalizumab 450 mg between 2016 and 2018.

The mean Urticaria Activity Score over 7 days decreased from 18,6 to 5,1 and the mean Urticaria Control Test score increase from 8,6 to 12 in group 2 participants after a mean 4,3 courses of omalizumab 450 mg. Of all 13 participants from group 2, 6 of them had a complete response, and 3 a good disease control. Those whose response to treatment was lower had low baseline total IgE levels (<43 IU/mL).

In conclusion, this team demonstrated that higher doses of omalizumab are effective and safe in patients with chronic spontaneous urticaria that is unresponsive to omalizumab 300 mg. Also, they predict that lower baseline total IgE levels might be related to a nonresponse to omalizumab and the need for higher doses.

This document is only available for registered healthcare professionals

Login
Bilastina y anticuerpos anti-

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

By | Selected articles
Ivan Cherrez-Ojeda, et al. World Allergy Organization Journal

A retrospective, observational study assessed 72 Latin American patients with chronic urticaria treated with omalizumab to evaluate patient-reported outcomes in management of their disease, as well as omalizumab effectiveness and treatment patterns in real-life setting.

Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control and quality of life at baseline and follow-up.

Omalizumab is a guideline-recommended second-line alternative anti-IgE monoclonal antibody in case of antihistamine refractoriness. It has been shown to be effective in patients with chronic autoimmune urticaria who were symptomatic despite antihistamine therapy.

From the 72 participants, 44 (80,0%) responded to omalizumab at some point of the treatment. Omalizumab 300 mg was associated with earlier response compared to lower doses. Regardless of dosage, most participants improved quality of life. Fifteen participants interrupted omalizumab before the third month of treatment

In conclusion, most patients responded to the treatment and improved their quality of life at a lower dose than the 300 mg recommended by the guidelines and clinical trials.

This document is only available for registered healthcare professionals.

Acceder

Autoimmune theories of chronic spontaneous urticaria

By | Selected articles

Sonali J. Bracken, Soman Abraham and Amanda S. MacLeod

Different theories exist to describe the pathogenesis of chronic spontaneous urticaria. A group of investigators highlighted in this study the evidence surrounding the autoimmune pathogenesis of chronic urticaria, a condition which persists for more than 6 weeks in duration and occurs in the absence of an identifiable provoking factor.

Chronic spontaneous urticaria results from pathogenic activation of mast cells and basophils, which releases proinflammatory mediators of urticaria. Recent data suggests that chronic spontaneous urticaria may involve contributions from both immunoglobin G (IgG)-specific and immunoglobulin E (IgE)-specific autoantibodies against a vast array of antigens that can span beyond those found on the surface of mast cells and basophils, contributing to the severity of the disease and predisposing people to the development of additional autoimmune diseases.

People with chronic spontaneous urticaria mediated by IgE autoantibodies appear to have a faster onset of improvement in response to omalizumab than those with IgG-mediated disease.

This document is only available for registered healthcare professionals

Login
Terapia combinada de azelastina intranasal y propionato de fluticasona

Intranasal azelastine and fluticasone as combination therapy for allergic rhinitis: therapy for allergic rhinitis: systematic review and meta-analysis

By | Selected articles

Peter M. Debbaneh, Anna K. Bareiss, Sarah K. Wise and Edward D. McCoul

(2019) Otolaryngology – Head and Neck Surgery

La terapia de combinación con azelastina intranasal y propionato de fluticasona es una opción para el tratamiento de la rinitis alérgica. Esta revisión sistemática y meta-análisis examina la literatura existente para determinar la eficacia en el tratamiento de la rinitis alérgica en comparación con la monoterapia.

This document is only available for registered healthcare professionals

Login
Urticaria Espontánea Crónica

Tumor necrosis factor-alpha and Fas/Fas ligand signaling pathways in chronic spontaneous urticaria

By | Selected articles
Grzanka R, Damasiewicz-Bodzek A, Kasperska-Zajac A.

Tumor necrosis factor-alpha (TNF-a) is a key inflammatory and apoptotic mediator in urticaria. However, its role is still unclear in the apoptosis-inducing pathways in chronic spontaneous urticaria.

A group of people with chronic spontaneous urticaria and healthy people had their circulating concentrations of TNF-a, soluble TNF-a receptor types 1 and 2 and soluble Fas and Fas Ligand measured using enzyme-linked immunosorbent assay.

TNF-a and soluble TNF-a receptor types 1 and 2 concentrations were significantly higher in people with moderate-to-severe chronic spontaneous urticaria than healthy people. No significant differences were found between people with mild urticaria and healthy people. There were no differences observed in Fas and Fas Ligand concentrations in all participants.

In conclusion, chronic spontaneous urticaria is associated with the activation of the TNF-a/receptors signalling pathway marked by increased circulating concentrations of TNF-a and soluble TNF-a receptor types 1 and 2. In contrast, the circulating soluble Fas/Fas Ligand system is not up-regulated in chronic urticaria and does not seem to be an useful marker for the disease.

This document is only available for registered healthcare professionals.

Acceder
Congreso bilastina

Bilastine symposium at the EAACI 2019 congress

By | Articles about Bilastine

On the occasion of the celebration of the 38th congress of the European Academy of Allergy and Clinical Immunology (EAACI), which will take place between 1 and 5 June in Lisbon, Faes Farma announces the holding of an important symposium specifically aimed at its antihistamine. own research, bilastine.

This meeting is scheduled for June 2 at 5:30 pm in Hall 5 of the conference venue.

With the title “BILASTINE: A lifetime companion. Value every moment of your life. “, counts as chairman with Prof. Martin Church (UK) and three specialist speakers of international prestige.

The first presentation will be made by Dr. Ralph Mösges (Germany) and will deal with the on-off relationship of patients with their treatments of allergic rhinitis.

The second presentation will be offered by Dr. Marysia Recto (Philippines) and will analyze the needs not covered in patients with urticaria.

Finally, Dr. Zoltán Nóvak (Hungary) will show the need for antihistamine treatments not to affect the life and daily activities of pediatric allergic patients.

You are cordially invited.

You can access the audiovisual contents of other editions in this link.

Investigación clínica sobre bilastina

Shortened up-dosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen season

By | Selected articles

Mösges R, Breitrück NY, Allekotte S, Shah-Hosseini K, Dao VA, Zieglmayer P, Birkholz K, Hess M, Bastl M, Bastl K, Berger U, Kramer MF, Guethoff S.

This study compared a rapid home-based up-dosing schedule for sublingual immunotherapy (SLIT) drops containing tree pollen allergens with two previously established schedules. Furthermore, the clinical effect of the SLIT was investigated with respect to patients’ first pollen season under treatment.

This document is only available for registered healthcare professionals

Login
Estudio de bilastina en pacientes japoneses

Association of positive and negative autologous serum skin test responses with clinical features of chronic spontaneous urticaria in Asian patients: A systematic review and meta-analysis

By | Selected articles

Niu XL, Zhu LL, Shi MH, Zhang YJ, Gao XH, Qi RQ.

Previous studies on the correlation between positive autologous serum skin test (ASST) responses and the clinical features of patients with chronic spontaneous urticaria (CSU) have provided conflicting results. To evaluate the significance of ASST responses in CSU, a variety of databases were searched from inception to March 2018 to identify relevant studies on CSU.

This document is only available for registered healthcare professionals

Login

La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.

Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.

ACEPTAR